SUMO belongs to a growing number of ubiquitin-like proteins that covalently modify their target proteins. Although some evidence supports a role of SUMO modi®cation in regulating protein stability, most studied examples support a model by which SUMO alters the interaction properties of its targets, often aecting their subcellular localization behavior. Examination of the PML nuclear bodies, whose principal components are SUMO-modi®ed, has revealed this modi®cation to be essential for their structural and functional integrity. This and other examples thus support the view that SUMO regulates the stability not of individual proteins, but rather that of entire multiprotein complexes. Oncogene (2001) 20, 7243 ± 7249.
Introduction
Post-translational protein modi®cations such as phosphorylation, glycosylation, acetylation and methylation have achieved the status of the commonplace, whereas, with the exception of ubiquitin, proteins that modify other proteins have remained, until recently, exceptional curiosities. Perhaps it is the colinearity of gene, messenger RNA and protein, handed down in the Central Dogma of molecular biology, that has left us somewhat unprepared for the existence of branched, or non-linear proteins? Nevertheless, ®ve protein conjugation systems distinct from ubiquitylation have received much attention recently (Table 1) . In all ®ve, the modi®cation reaction is carried out in distinct pathways that are analogous to ubiquitylation, and further, all ®ve modi®ers are structurally related to ubiquitin. Indeed, although Apg8p/Aut7p displays almost no primary sequence homology to ubiquitin, the recent Xray structure determination of its mammalian ortholog GATE-16 did reveal the ubiquitin fold structure (Paz et al., 2000) . It is thus tempting to speculate that there may be (numerous?) other ubiquitin-like proteins that await discovery because their similarity to ubiquitin is non-obvious. (For an evolutionary perspective on these and possible other modi®cation systems, see Hochstrasser, 2000) . Finally, none of these ubiquitin-like modi®ers appear to be directly implicated in the proteasomal destruction of their target proteins, although functional links with the ubiquitin system exist in some cases.
In this review we will focus on one of these modi®ers, SUMO (`small ubiquitin-like modi®er'; see also recent reviews by Melchior, 2000; MuÈ ller et al., 2001) . Within the context of the present volume, particular emphasis will be given to the role of SUMO modi®cation pathway in the function and dynamics of the PML nuclear bodies.
The SUMO pathway SUMO proteins have been variously called Smt3p (`suppressor of MIF2' in budding yeast; Meluh and Koshland, 1995) Pmt3p (in ®ssion yeast; Tanaka et al., 1999) , PIC-1 (`PML-interacting clone 1; Boddy et al., 1996) , GMP1 (`GAP modifying protein 1; Matunis et al., 1996) , Ubl1 (Ubiquitin-like protein 1; Shen et al., 1996) and Sentrin (Okura et al., 1996) . Yeasts and Drosophila contain only a single SUMO-encoding gene, whereas mammals express three SUMO paralogs. All are approximately 100-residue proteins containing weak but signi®cant (18 ± 20%) primary sequence homology to ubiquitin in the carboxyterminus and a 15 ± 20 amino acid variable, unstructured region in the aminoterminus. (Bayer et al., 1998) . Recent work has uncovered important dierences in the behavior of mammalian SUMO-1 versus SUMO-2/3 proteins. The former exists mainly in the conjugated form, whereas SUMO2/3 proteins are found largely in the free state (Saitoh and Hinchey, 2000) . Moreover, SUMO-1 and SUMO-2/3 proteins conjugate distinct substrate sets in vivo and cellular stress (e.g. heat shock) rapidly induces the conjugation of SUMO-2/3, whereas the conjugation pattern of SUMO-1 remains essentially unaected.
Since most known SUMO substrates are nuclear proteins, it has been suggested that sumoylation is a nuclear process (Rodriguez et al., 2000) . Nuclear localization of SP100, for example, is a requirement for sumoylation since a cytoplasmic mutant of this protein remains unmodi®ed . Moreover, arti®cial fusion proteins harboring a SUMO targeting motif (e.g. from p53 or IkBa, see below) are modi®ed only if they also contain a functional nuclear localization sequence (Rodriguez et al., 2000) . It remains to be demonstrated, though, whether cyto-plasmic proteins (e.g. RanGAP1, GLUT1, -4; Giorgino et al., 2000) require translocation to the nucleus to undergo modi®cation, or whether, in speci®c cases, sumoylation may also occur in the cytoplasm.
The covalent attachment of SUMO to its targets utilizes a speci®c set of enzymes for maturation (Cterminal hydrolase), activation (E1), and conjugation (E2, and possibly E3) to form an isopeptide link between the SUMO C-terminal glycine and a lysine of the target protein (Figure 1 ).
E1
The ATP-dependent activation step in the SUMO pathway results in the formation of a high-energy thioester bond between the C-terminal Glycine residue of SUMO and an E1 enzyme, and is achieved by the dimeric Aos1/Uba2 enzyme (also called SAE1/SAE2, or Sua1/Uba2; Desterro et al., 1999; Gong et al., 1999; Okuma et al., 1999) .
E2
Unlike ubiquitylation, for which numerous ubiquitin conjugating enzymes (Ubc's) have been described, the SUMO pathway apparently uses only a single E2 enzyme, Ubc9 (Gong et al., 1997; Johnson and Blobel, 1999; Schwarz et al., 1998; Lee et al., 1998; Saitoh et al., 1998) . Through a conserved Cys residue (Cys93), Ubc9 forms a thioester linkage with SUMO prior to conjugation with the target protein. Besides its catalytic activity, Ubc9 may also perform other cellular functions. The transcriptional activity of the androgen receptor, for example, (AR) is enhanced by Ubc9 overexpression (Poukka et al., 1999) . Interestingly, this is also the case when SUMO conjugating activity is abrogated by mutation of the SUMO acceptor site Cys93, suggesting that Ubc9 catalytic function can be uncoupled from its AR coregulator function.
E3?
For ubiquitylation, E3 ligase enzymes provide a direct or indirect transfer function of ubiquitin from the E2 to the substrate (for reviews see Weissman, 2001; Joazeiro and Weissman, 2000; Tyers and Willems, 1999) . Whether the SUMO system possesses or even requires an E3-like activity remained doubtful since a recombinant target protein can be sumoylated in vitro using only`matured' SUMO (SUMO-GG) and recombinant E1 (Aos1/Uba2) and E2 (Ubc9) enzymes in the presence of ATP (Desterro et al., 1997 (Desterro et al., , 1998 Okuma et al., 1999) . However, given the uniqueness of the E2 enzyme for SUMO (Ubc9) versus the multitude of these enzymes for ubiquitylation, it is dicult to Figure 1 The SUMO pathway. SUMO proteins are translated as pre-proteins that are cleaved by a hydrolase to expose a Cterminal Gly residue which then forms thioester intermediates with the E1 (Aos1/Uba2), E2 (Ubc9) and possibly E3 enzymes, before being coupled to the e-aminogroup of a Lys residue of the substrate protein. Analysis of multiple substrates has revealed a loose consensus sequence, the`LKXE' motif, for the SUMO acceptor site . Demodifying isopeptidases likely represent important regulatory elements of the pathway envisage how this simple system could be regulated or possess substrate speci®city in vivo. Thus, it is possible that an E3 ligase protein or protein complex for SUMO still awaits identi®cation.
Ulp (SENPs/SUSPs)
A number of SUMO-speci®c proteases have been isolated that carry out SUMO maturation (C-terminal hydrolases) and deconjugation (isopeptidases). The ®rst of these, Ulp1 (`ubiquitin-like protease'), was isolated from yeast (Li and Hochstrasser, 1999) and carries out both reactions. Since then, numerous additional enzymes have been isolated from yeasts and mammalian cells. (Li and Hochstrasser, 2000; Suzuki et al., 1999; Gong et al., 2000b; Nishida et al., 2000; Kim et al., 2000; Schwienhorst et al., 2000) . These have been variously called SENPs (for`Sentrin-speci®c protease'; Gong et al., 2000b; Yeh et al., 2000) , SUSPs (SUMOspeci®c protease; Kim et al., 2000) or SMT3IP1 (Nishida et al., 2000) . The substrate speci®city of these enzymes appears to be partially regulated by subcellular partitioning. For example, the nuclear enzyme SENP1 cleaves SUMO conjugates of the nuclear PML protein but not of the cytoplasmic RanGAP1 (Gong et al., 2000a) . Furthermore, speci®city for a particular SUMO isoform has also been demonstrated. The SMT3IP1 protease, which apparently exhibits only isopeptidase activity, displays a preference for SUMO-2 over SUMO-1 conjugates (Nishida et al., 2000) .
The biological function of sumoylation: SUMO substrates
The presently known SUMO target proteins fall into multiple categories (see Table 2 ), such as transcription factors, signal transducers or`structural' proteins, making a simple explanation for SUMO's biological role unlikely. Nevertheless, the following examples illustrate two models for a general understanding of SUMO function.
RanGAP1: substrate re-targeting
The study of the nuclear import factor RanGAP1 (Ran GTPase activating protein 1) provided the ®rst evidence that, like ubiquitin, SUMO-1 is covalently attached to its target protein. Three groups independently showed that sumoylation is a prerequisite for the cytosolic RanGAP1 to associate with RanBP2 at the nuclear pore complex to form the functional nuclear import machinery (Matunis et al., 1996 Mahajan et al., 1997 Mahajan et al., , 1998 Saitoh et al., 1998) . Thus in this example, sumoylation alters the binding speci®city and hence the localization of the target protein.
Interestingly, it was also shown that RanBP2 binds Ubc9, and is itself subject to SUMO-1 modi®cation (Saitoh et al., 1998) , although the in vivo signi®cance of this modi®cation remains unknown.
IkBa and Mdm2: antagonizing ubiquitin
A quite dierent model for SUMO function has been invoked in the case of the NF-kB inhibitor IkBa. This protein, whose function as inhibitor relies on the cytoplasmic sequestration of the NF-kB transcription factor, has been shown to be sumoylated on the same acceptor lysine as that targeted by ubiquitin (Desterro et al., 1998) . Hence sumoylation antagonizes ubiquitylation, resulting in the stabilization of IkBa and the consequent reduction in NF-kB transcriptional activity. A similar competition between sumoylation and ubiquitylation has also been reported for the Mdm2 protein, the E3 ubiquitin ligase for p53 (Buschmann et al., 2000) . In preventing the attachment of ubiquitin to the same acceptor, SUMO stabilizes Mdm2 and hence enhances the ubiquitin-mediated degradation of p53. Whether Mdm2 is SUMO-modi®ed, though, has recently been called into question ; MuÈ ller and Dejean, unpublished results), and additional experimentation may be required.
SUMO and nuclear bodies

PML
The PML nuclear bodies (NBs) have provided a fertile ®eld of investigation for the elucidation of the biological role of sumoylation because their two principal components, PML and SP100 are SUMOmodi®ed (Sternsdorf et al., 1997; MuÈ ller et al., 1998) . The ®rst clue that SUMO modi®cation plays a critical role in NB dynamics came from the observation that trivalent arsenic leads to a dramatic increase in PML sumoylation (MuÈ ller et al., 1998) , thus correlating with the observed increase in NB size in normal cells and the re-aggregation of the microspeckled NB derivatives in leukemic APL cells (see contribution by de TheÂ in this volume). Fractionation studies further showed that the bulk of the SUMO-modi®ed PML resides in the insoluble NB-associated fraction (MuÈ ller et al., 1998) . Finally, the examination of PML 7/7 cells showed the other normally NB-associated proteins (SP100, Daxx, ISG20, BLM, CBP) to be nuclear diuse or mislocalized (Ishov et al., 1999; Zhong et al., 2000) . These results, which suggested that PML and not the other NB proteins constitutes the NB`scaold' were extended by`add-back' experiments with wild-type PML and a mutant derivative (Kamitani et al., 1998; Duprez et al., 1999) in which the three SUMO acceptor lysines had been mutated. Whereas re-addition of wt PML to PML 7/7 cells led to the re-recruitment of the other NB proteins into PML-containing speckles, the non-modi®able PML mutant did not (Ishov et al., 1999; Zhong et al., 2000) . Taken together, these results strongly support the notion that proper nuclear body formation requires SUMO-modi®ed PML. (For results somewhat at variance with this conclusion, see review by de TheÂ in this volume.)
Interestingly, besides PML, three other examples implicate SUMO in the alteration of its substrate's subnuclear localization. HIPK2, a kinase cofactor of homeodomain transcription factors, localizes to subnuclear speckles when modi®ed by SUMO (Kim et al., 1999) . Similarly, the ets-related transcriptional repressor TEL assembles into nuclear body-like structures (TEL bodies) when SUMO-modi®ed (Chakrabarti et al., 2000) . Finally, the p53-related p73a protein has been shown to relocalize from the soluble to the insoluble nuclear fraction upon sumoylation (Minty et al., 2000) . SP100 and SUMO: a`covalent link' between nuclear bodies and chromatin? SP100 represents the other nuclear body component modi®ed by SUMO (Sternsdorf et al., 1997) . Whether SUMO modi®cation of SP100, like that of PML, is a prerequisite for proper targeting to the nuclear bodies, however, remains an open question. Although a mutant SP100 protein unable to be modi®ed does target the nuclear bodies , it cannot be excluded, in the absence of an SP100
background, that this targeting is not due to dimerization with the endogenous protein. SP100 exists as multiple products derived from alternative splicing. Two of these variants, (SP100-HMG, and SP100C) contain C-terminal domains (HMG1/2, PHD ®nger/ Bromodomain) that point to a function at the chromatin level (Seeler et al., 1998 (Seeler et al., , 2001 Guldner et al., 1999) . Furthermore, SP100 interacts and colocalizes with HP1 (hetrochromatin protein 1), and GAL4 DNA binding domain fusions of SP100 behave as potent transcriptional repressors (Seeler et al., 1998; Lehming et al., 1998) . Recent in vitro experiments provided evidence that sumoylation of SP100 enhances binding to HP1a (Seeler et al., 2001) , suggesting that the interplay between nuclear bodies and chromatin could be regulated by SUMO and that sumoylation does not necessarily result in the creation of new interaction interfaces (as is the case for RanGAP1), but may play a role in stabilizing existing ones. The transcriptional co-repressor and nuclear body protein Daxx provides a further example for the SUMO-regulated dynamic interplay between the nuclear bodies and the chromatin compartment. In PML 7/7 cells the absence of PML nuclear bodies causes Daxx to accumulate in centromeric heterochromatin, from where it is recruited back to the nuclear bodies upon addition of SUMOmodi®able PML (Ishov et al., 1999; . Yeast two-hybrid and biochemical analysis suggest this to be due to a direct interaction between SUMOmodi®ed PML and Daxx. Indeed, further work demonstrated that Daxx recruitment by PML correlates with a loss in Daxx repressor function Lehembre et al., 2001) .
SUMO and viral infection
The ®nding that early gene products from several DNA viruses (reviewed in Maul, 1998 , and by Everett, this volume) alter or disrupt the PML nuclear bodies provided much impetus to investigate the eects of viral proteins on SUMO conjugation. It could thus be shown that the disruption of the nuclear bodies by Herpes Simplex virus (HSV-) ICPO, cytomegalovirus (CMV-) IE1 (MuÈ ller and Dejean, 1999) and EpsteinBarr virus (EBV) immediate-early protein BZFL1 (Adamson and Kenney, 2001) correlates with the abrogation of sumoylation of PML and SP100. In contrast, the adenoviral E4ORF3 product, while also altering, but not entirely disrupting the PML nuclear bodies, causes no such eect (MuÈ ller and Dejean, 1999) . Later work extended these ®ndings by showing that some immediate-early viral gene products are themselves substrates for sumoylation. These include CMV-IE1 (MuÈ ller and Dejean, 1999) , and -IE2 (Ahn et al., 2001; Hofmann et al., 2000) , bovine and human papillomavirus (BPV, HPV) E1 (Rangasamy et al., 2000) and the EBV-BZFL1 (Adamson and Kenney, 2001) . The signi®cance here of sumoylation remains poorly understood, but for BPV-E1 it appears necessary for normal nuclear localization, whereas for CMV-IE2, sumoylation was shown to enhance IE2-mediated transactivation. Taken together, these results provide additional evidence that SUMO modi®cation plays a critical role in nuclear body dynamics, although it remains to be determined whether viral-induced PML and SP100 de-sumoylation causes nuclear body dispersal or vice versa.
Transcription factors
The numerous transcription factors modi®ed by SUMO suggest that sumoylation can in¯uence transcriptional regulation directly. Sumoylation of p53, for example, leads to a mild enhancement of the transcriptional and apoptotic response (Gostissa et al., 1999; Rodriguez et al., 1999; MuÈ ller et al., 2000) .
Whether there is a relationship between the senescenceinduced recruitment of p53 to the PML nuclear bodies (see review by Pelicci this volume and references therein) and its sumoylation, is unknown.
The activity of the Drosophila NF-kB homolog Dorsal is similarly upregulated by sumoylation, but by a mechanism that enhances the nuclear translocation of this transcription factor (Bhaskar et al., 2000) . Thus sumoylation aects the NF-kB pathway in both ies and in mammals, albeit in a dierent place and with opposite eect. Also in Drosophila, the transcription factor Tramtrack-69 (Ttk69) has been shown to represent an important SUMO substrate . The role played by SUMO here is unknown but these authors showed that Ttk69 and SUMO colocalize on polytene chromosomes, and further, that in interphase nuclei SUMO localizes to speckles reminiscent of the PML nuclear bodies of vertebrates.
The SUMO-mediated transcriptional enhancement of the HSF2, a factor that regulates heat shock protein (hsp) gene expression and that also colocalizes with the PML nuclear bodies, occurs by yet another mechanism. Here sumoylation activates the DNA-binding function of HSF2 by targeting the DNA binding domain (Goodson et al., 2001) .
By contrast, mild negative eects of sumoylation on transcriptional activation have been reported for c-Jun and for the androgen receptor (Poukka et al., 2000) .
SUMO and higher-order (nucleo-) protein complexes
The PML nuclear bodies or the nuclear pore complex are not the only large subcellular protein complexes aected by SUMO or by the other components of the modi®cation pathway. Genetic evidence from yeast implicates SUMO in the dynamics of centromere structure: indeed, the gene encoding the budding yeast SUMO (SMT3p) protein was initially isolated as a high-copy suppressor of mutations of Mif2, the yeast homolog of the centromere protein CENP-C (Meluh and Koshland, 1995) . Also in budding yeast, it was shown that bud neck (septin ring) formation, essential for cytokinesis, is subject to regulation by SUMO (Johnson and Blobel, 1999; Takahashi et al., 1999) . Sumoylation of three septin ring components (Cdc3p, Cdc11p and Sep7) is essential for the proper cell cycleregulated disassembly of the septin ring. In ®ssion yeast, loss of SUMO (Pmt3p; Tanaka et al., 1999) or Ubc9 (hus5+; al-Khodairy et al., 1995) activity manifests itself as cell-cycle defects, often leading to chromosome loss or genomic instability, and whose structural basis lies in the dysfunction of centromeres, kinetochores, telomeres or the mitotic spindle apparatus. In Drosophila, dominant mutations in the lesswright (lwr) locus, the gene encoding the Drosophila Ubc9 homolog suppress nondisjunction (nod) mutations that aect female meiosis (Apionishev et al., 2001) . In mammalian cells, Ubc9 has been localized to synaptonemal complexes together with Rad51/Rad52 proteins (Kovalenko et al., 1996) , although the possible SUMO substrates are unknown. Similarly, the ®ndings that topoisomerases 1 and 72 (TOP1, -2; (Mao et al., 2000a,b) , and WRN, the Werner's syndrome RecQtype helicase (Kawabe et al., 2000) list among SUMO substrates further underscores the potential importance of sumoylation in regulating or maintaining higherorder nucleo-protein complexes.
Conclusions and perspectives
The ubiquitin and Nedd8/Rub1 modi®cation systems are critically involved as causes or regulators, respectively, of proteasomal protein degradation. For the SUMO system, links to protein degradation appear to be the exception. Rather, sumoylation modi®es its substrate's interaction with partner proteins, often leading to visible changes in subcellular compartmentalization. Moreover, the physical and/or genetic association of SUMO (or SUMO pathway components) with large multiprotein complexes (nuclear lamina, PML nuclear bodies, centromeres/kinetochores, etc.) suggests that sumoylation constitutes an imprint that tells a speci®c protein complex to stay together or to respond to external stimuli. Finally, we do not yet know for how many of the reported SUMO target proteins a bona ®de role can be found under in vivo physiological conditions, since, by necessity, most studies to date have been limited to arti®cial systems (transformed cell lines, exogenous overexpression, etc.). Thus, the study of animal models in which components of the SUMO pathway have been inactivated, or in which mutant SUMO target proteins are expressed, should receive high priority in future research. Only then can we tell whether simple models will suce to explain the multitude of observed phenomena surrounding the covalent modi®cation of proteins by SUMO.
